alendronate has been researched along with Esophageal Diseases in 13 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Esophageal Diseases: Pathological processes in the ESOPHAGUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We present a case of esophageal ulcerations caused by alendronate (Fosamax), a recently marketed medication." | 8.79 | A new probable increasing cause of esophageal ulceration: alendronate. ( Colina, RE; Kikendall, JW; Smith, M; Wong, RK, 1997) |
| "We present a case of esophageal ulcerations caused by alendronate (Fosamax), a recently marketed medication." | 4.79 | A new probable increasing cause of esophageal ulceration: alendronate. ( Colina, RE; Kikendall, JW; Smith, M; Wong, RK, 1997) |
| "Ingestion of alendronate sodium (Fosamax) by osteoporotic patients can be associated with esophagitis and esophageal ulcer." | 3.70 | Alendronate-associated esophageal injury: pathologic and endoscopic features. ( Abraham, SC; Cruz-Correa, M; Lee, LA; Wu, TT; Yardley, JH, 1999) |
| "Alendronate use was not associated with a significant increase in upper GI tract events among women at increased risk for these events (those aged > or =75 years with previous upper GI tract disease or using nonsteroidal anti-inflammatory drugs)." | 2.69 | Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. ( Bauer, DC; Black, D; Ensrud, K; Freedholm, D; Hochberg, M; Musliner, T; Nevitt, M; Thompson, D, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (46.15) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McCadden, L | 1 |
| Leonard, CG | 1 |
| Primrose, WJ | 1 |
| Adachi, JD | 1 |
| Faraawi, RY | 1 |
| O'Mahony, MF | 1 |
| Nayar, A | 1 |
| Massaad, R | 1 |
| Evans, JK | 1 |
| Yacik, C | 1 |
| Ueda, K | 1 |
| Muto, M | 1 |
| Chiba, T | 1 |
| Lanza, F | 2 |
| Cryer, B | 1 |
| Binkley, N | 1 |
| Simonelli, C | 1 |
| Lewiecki, EM | 1 |
| Chen, E | 1 |
| Petruschke, RA | 1 |
| Mullen, C | 1 |
| de Papp, AE | 1 |
| Terashima, T | 1 |
| Hiramatsu, K | 1 |
| Shimatani, A | 1 |
| Matsuda, M | 1 |
| Ogino, H | 1 |
| Satomura, Y | 1 |
| Noda, Y | 1 |
| Liberman, UI | 1 |
| Hirsch, LJ | 1 |
| Sorrentino, D | 1 |
| Trevisi, A | 1 |
| Bernardis, V | 1 |
| DeBiase, F | 1 |
| Labombarda, A | 1 |
| Bartoli, E | 1 |
| Colina, RE | 1 |
| Smith, M | 1 |
| Kikendall, JW | 1 |
| Wong, RK | 1 |
| Kaye, PS | 1 |
| Abraham, SC | 1 |
| Cruz-Correa, M | 1 |
| Lee, LA | 1 |
| Yardley, JH | 1 |
| Wu, TT | 1 |
| Bauer, DC | 1 |
| Black, D | 1 |
| Ensrud, K | 1 |
| Thompson, D | 1 |
| Hochberg, M | 1 |
| Nevitt, M | 1 |
| Musliner, T | 1 |
| Freedholm, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Compare the Safety and Tolerability of an Oral Buffered Solution of Alendronate Sodium 70 mg Once-Weekly Versus Placebo for the Treatment of Osteoporosis in Postmenopausal Women[NCT00092027] | Phase 3 | 454 participants (Actual) | Interventional | 2003-03-19 | Completed | ||
| A 5-year, Double-blind, Randomized, Placebo-controlled Extension Study to Examine the Long-term Safety and Efficacy of Oral Alendronate in Postmenopausal Women Who Previously Received Alendronate in Conjunction With the Fracture Intervention Trial[NCT00398931] | Phase 3 | 1,099 participants (Actual) | Interventional | 1998-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for alendronate and Esophageal Diseases
| Article | Year |
|---|---|
Bisphosphonate-induced osteonecrosis of the ear canal: our experience and a review of the literature.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Densi | 2018 |
Bisphosphonate mucosal injury--the end of the story?
Topics: Alendronate; Diphosphonates; Duodenal Ulcer; Duodenum; Esophageal Diseases; Esophagus; Female; Human | 2003 |
A new probable increasing cause of esophageal ulceration: alendronate.
Topics: Adult; Alendronate; Biopsy; Esophageal Diseases; Esophagogastric Junction; Esophagoscopy; Female; Hu | 1997 |
4 trials available for alendronate and Esophageal Diseases
| Article | Year |
|---|---|
Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Double-Blind Method; | 2009 |
A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Collagen; | 2005 |
Esophagitis and alendronate.
Topics: Alendronate; Diphosphonates; Esophageal Diseases; Esophagitis; Female; Humans; Osteoporosis, Postmen | 1996 |
Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Digestive System; Double-Blind Method; Duodenal | 2000 |
6 other studies available for alendronate and Esophageal Diseases
| Article | Year |
|---|---|
A case of esophageal ulcer caused by alendronate sodium tablets.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Endoscopy, Gastrointes | 2011 |
An esophageal ulcer mimicking advanced esophageal cancer in a patient on alendronate sodium treatment for osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Esophageal Diseases; Esophag | 2006 |
Postmarketing surveillance indicates need for better education of patients taking alendronate.
Topics: Alendronate; Diphosphonates; Esophageal Diseases; Esophagitis; Humans; Patient Education as Topic; P | 1996 |
Esophageal ulceration due to alendronate.
Topics: Adult; Alendronate; Esophageal Diseases; Humans; Male; Osteoporosis; Ulcer | 1996 |
Gastric hemorrhage and ulceration in hiatal hernia sac associated with alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Esophageal Diseases; Female; Gastrointestinal Hemorrhage; Hern | 1999 |
Alendronate-associated esophageal injury: pathologic and endoscopic features.
Topics: Aged; Aged, 80 and over; Alendronate; Esophageal Diseases; Esophagitis; Esophagoscopy; Esophagus; Fe | 1999 |